Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Treasury Shares (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Treasury Shares for 5 consecutive years, with $802.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $802.5 million, compared with a TTM value of $802.5 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $802.5 million, changed 0.0% over the prior year.
  • Treasury Shares was $16.2 million for Q4 2025 at Agios Pharmaceuticals, roughly flat from $16.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $16.2 billion in Q1 2022 and bottomed at $7.1 million in Q1 2021.
  • Average Treasury Shares over 5 years is $7.3 billion, with a median of $2.7 billion recorded in 2021.
  • Peak annual rise in Treasury Shares hit 51.69% in 2022, while the deepest fall reached 0.0% in 2022.
  • Year by year, Treasury Shares stood at $802.5 million in 2021, then changed by 0.0% to $802.5 million in 2022, then changed by 0.0% to $802.5 million in 2023, then changed by 0.0% to $802.5 million in 2024, then changed by 0.0% to $802.5 million in 2025.
  • Business Quant data shows Treasury Shares for AGIO at $802.5 million in Q4 2025, $802.5 million in Q3 2025, and $802.5 million in Q2 2025.